Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Connect Biopharma Holdings Limited (CNTB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. These filings give investors structured insight into the clinical, financial, and corporate events that shape this clinical-stage biopharmaceutical company focused on asthma, COPD, and related inflammatory diseases.
Connect Biopharma’s recent Forms 8-K have covered topics such as quarterly financial results, business updates, and material corporate actions. Examples include announcements of second and third quarter financial results, the initiation and progress of Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart, and the company’s decision to terminate its American Depositary Receipt program and directly list its ordinary shares on the Nasdaq Global Market. Other 8-K filings describe board changes, including the appointment of an additional director, and regulatory milestones such as the submission of a New Drug Application for rademikibart in atopic dermatitis by the company’s exclusive licensee in China.
Filings also document insider-related information and regulatory disclosures under Regulation FD, such as updates on share purchases by senior executives and communications about collaboration activities with Simcere Pharmaceutical Co., Ltd. in Greater China. These documents complement Connect Biopharma’s press releases by providing formal, SEC-compliant descriptions of material events.
On Stock Titan, CNTB filings are updated as new documents are posted to the SEC’s EDGAR system. Users can review individual filings to understand how Connect Biopharma reports its clinical progress with rademikibart, capital markets decisions, governance changes, and other significant developments that may be relevant to an assessment of CNTB stock.
Connect Biopharma Holdings has received a Notice of Effectiveness from the SEC for their Form F-3 registration statement (File No. 333-287918), which became effective on June 26, 2025 at 4:00 P.M.
Form F-3 is a securities registration statement used by foreign companies to register various types of securities offerings in the United States. The effectiveness of this filing indicates that Connect Biopharma can now proceed with their planned securities offering as outlined in the registration statement.
This development is significant for investors as it enables the company to access U.S. capital markets and potentially raise additional funds through various securities offerings, including debt or equity securities, depending on the specifics outlined in the F-3 registration statement.